Меню
Идёт набор NCT07173868

FDG PET-CT in Advanced Breast Cancer

— Наблюдательное Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available, If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT. Базовые параметры: от 19 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
South Korea
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Prospective Cohort Study Comparing Metabolic Response Evaluation by F-18 FDG PET-CT Versus Conventional Imaging for Outcome Stratification in Patients With Advanced Breast Cancer Receiving First-line Systemic Therapy

Обзор

This study is a prospective cohort study comparing metabolic response evaluation by F-18 FDG PET-CT versus conventional imaging for outcome stratification in patients with advanced breast cancer receiving first-line systemic therapy.

Подробное описание

PET-CT, CE-CT ± bone scan are performed before and during treatment (6, 12, 24, 48 weeks) of the first systemic treatment in a total of 100 patients with advanced breast cancer, and some patients analyze ctDNA-based MRD by collecting blood at the same time point. We analyze the relationship between patient-specific responses and PFS, and compare the predictive performance of imaging and molecular indicators.

Первичные конечные точки

  • Follow up the response for 48 weeks after the start of the first systemic treatment [Срок оценки: Within 4 weeks prior to the start of primary systemic treatment]

Критерии участия

Критерии включения

  • 19 years of age or older
  • histologically confirmed metastatic or locally advanced breast cancer with no radical topical treatment available
  • If there is liver metastasis, which the researcher believes will be difficult to evaluate the response accurately with bone metastasis or CT
  • May or may not have measurable lesions in accordance with RECIST 1.1 criteria
  • Patients who meet the criteria for coverage of F-18 FDG PET-CT tests conducted for the purpose of evaluating treatment response according to the Health Insurance Review and Assessment Service's announcement
  • Patients scheduled to start primary systemic therapy for advanced breast cancer (endocrine therapy, targeted therapy, chemotherapy, immunotherapy or their combination therapy)
  • Patients willing to undergo continuous response assessments using F-18 FDG PET-CT and CE-CT (± bone scan if clinically necessary) at the time point specified in the study plan (before treatment, 6, 12, 24, 48 weeks after treatment) and willing to pay for the examination accordingly
  • ECOG Performance Status 0-2

Критерии исключения

  • a patient who has previously received systemic treatment for advanced breast cancer
  • Taboos for F-18 FDG PET-CT (e.g., uncontrolled diabetes) or intravenous contrast agents for CE-CT (e.g., severe allergies, severe renal dysfunction)
  • Pregnancy or lactation
  • At the same time, other primary malignancies (except when treatment has been completed for radical purposes) are known
  • Other medical conditions that, at the discretion of the researcher, may hinder participation in the study or affect the interpretation of the results
  • If you are unable to follow a research procedure or follow-up

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

South Korea · 1 центр
  • Samsung medical Center — Seoul

Идентификаторы

NCT: NCT07173868 · 2025-06-039

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗